Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst

Published 31/08/2023, 19:12
© Reuters.  Biotech Stock Crinetics Pharmaceuticals Positioned For Success In Chronic Endocrine Disorder Treatment, Says Analyst
CRNX
-

Benzinga - by Vandana Singh, Benzinga Editor.

Oppenheimer initiated coverage on Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) with an Outperform rating and a price target of $40.

The analysts Leland Gershell and Rohan Mathur note significant room for improvement in drugs targeting various chronic endocrine disorders. Current options either have suboptimal benefit/risk profiles, problematic administration routes, or inadequate frequency.

The well-understood biology of peptide hormone signaling through G protein-coupled receptors makes them the therapeutic targets of choice, and Crinetics Pharmaceuticals is distinguished by its ability to create oral, once-daily non-peptide drug candidates to endocrine GPCRs

Oppenheimer writes that Crinetics Pharmaceuticals is well-positioned to meaningfully improve the treatment condition for a growing number of chronic endocrine disorders through its non-peptide drug discovery capability against well-understood targets.

Phase 3 development success in acromegaly could pave the way for oral paltusotine to generate ~$250 million in peak sales, and next quarter's Phase 2 look in neuroendocrine tumors could bring ~2x that initial opportunity into focus.

The analysts hold a positive outlook for the forthcoming Phase 2 outcomes of the daily oral ACTH antagonist CRN04894, anticipating it will establish proof-of-concept for both Cushing's syndrome and Congenital adrenal hyperplasia. Additionally, CRNX is progressing towards addressing more common medical conditions, as its early-stage initiatives for Graves' disease/Thyroid eye disease and diabetes/obesity are advancing toward clinical trials.

Price Action: CRNX shares are up 6.90% at $17.66 on the last check Thursday.

Latest Ratings for CRNX

DateFirmActionFromTo
Nov 2021JMP SecuritiesInitiates Coverage OnMarket Outperform
Nov 2021Evercore ISI GroupInitiates Coverage OnOutperform
Nov 2021HC Wainwright & Co.MaintainsBuy
View More Analyst Ratings for CRNX

View the Latest Analyst Ratings

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.